COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  OutcomesOutcomes
  Global AdoptionAdoption
  Submit FeedbackFeedback
00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.35-1.02]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment38%0.62 [0.38-1.02]4/2314/17938% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Tau​2 = 0.07; I​2 = 49.9%Late treatment28%0.72 [0.52-0.99]121/441129/1,31828% improvementAll studies28%0.72 [0.57-0.92]125/672133/1,49728% improvement9 favipiravir COVID-19 studiesc19favipiravir.com 8/4/211 OT: comparison with other treatmentTau​2 = 0.03; I​2 = 29.6%; Z = 2.65 (p = 0.004)Effect extraction pre-specifiedLower RiskIncreased Risk
 
Search:  
Restrict:    All    Early    Late
4/29
Late Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 (Peer Reviewed) death, ↓26.1%, p=0.28 Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19
Details   Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
4/21
Late Zhao et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702 (Peer Reviewed) viral+, ↓59.0%, p=0.06 Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial
Details   RCT with 55 patients (36 favipiravir, 19 control) who were PCR+ after recovery, showing improved viral clearance with treatment.
4/19
Late Favipiravir Observational Study Group, Fujita Health University (Preprint) Favipiravir Observational Study Interim Report 3
Details   Retrospective analysis of favipiravir use in 10,986 hospitalized patients, including analysis of changes in clinical status and side effects. Common adverse events were uric acid level increase and liver function enzyme increase. Authors ..
4/17
Early Fujii et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013 (Peer Reviewed) Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients
Details   Retrospective 41 favipiravir patients finding that early treatment was more successful.
3/11
Late Solaymani-Dodaran et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107522 (Peer Reviewed) death, ↑19.2%, p=0.54 Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Details   RCT late stage patients (median SpO2 89), 193 treated with favipiravir, 187 with lopinavir/ritonavir, showing no significant differences in mortality, intubation, or ICU admission.
3/8
Late Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Details   Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study.
2/4
Early, Late Uçan et al., Research Square, doi:10.21203/rs.3.rs-175340/v1 (Preprint) Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Details   Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV,..
1/25
Early Dabbous et al., Archives of Virology, doi:10.1007/s00705-021-04956-9 (Peer Reviewed) death, ↓45.5%, p=0.12 Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
Details   RCT with 44 favipiravir patients and 48 CQ patients, showing non-statistically significant lower mortality, ventilation, and hospitalization time with favipiravir.
1/14
Early Karatas et al., Research Square, doi:10.21203/rs.3.rs-142868/v1 (Preprint) Early Onset Favipiravir Saves Lives
Details   Retrospective 180 hospitalized patients showing lower mortality when Favipiravir is given earlier. 17% of patients given Favipiravir within 3 days died, compared to 38% when given after 3 days.
11/17
Late Doi et al., Antimicrobial Agents and Chemotherapy, doi:10.1128/AAC.01897-20 (Peer Reviewed) A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Details   Small RCT comparing late and very late (7 and 14 days from fever onset) favipiravir. Viral clearance was non-statistically significantly improved with relatively early treatment. There was a reduction in time to defervescence, and a signi..
11/16
Early Udwadia et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.142 (Peer Reviewed) recov. time, ↓40.0%, p=0.03 Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial
Details   RCT with 75 favipiravir patients and 75 control patients showing reduced time to clinical cure and reduced time of viral shedding.
11/9
Late Khamis et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008 (Peer Reviewed) Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
Details   Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
11/5
Late Pushkar et al., NCT04542694 (Preprint) no recov., ↓14.1%, p=0.06 Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Details   RCT 200 patients showing improvements in clinical recovery and viral clearance with favipiravir. There is no paper available but results are posted in clinicaltrials.gov.
10/26
Early Ruzhentsova et al., SSRN, doi:10.2139/ssrn.3696907 (Preprint) hosp., ↓6.0%, p=0.49 Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19
Details   RCT 168 patients, 112 receiving favipiravir and 56 SOC, showing shorter time to clinical improvement and faster viral clearance with favipiravir.
9/30
Late Zhaao et al., Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2020.110825 (Peer Reviewed) Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
Details   Small study with 14 combined favipiravir/tocilizumab, 7 favipiravir, and 5 tocilizumab patients suggesting that tocilizumab combined with or without favipiravir can improve pulmonary inflammation and inhibit progression.
8/9
Late Ivashchenko et al., Clin. Infect. Dis., doi:10.1093/cid/ciaa1176 (Peer Reviewed) viral+, ↓46.4%, p=0.03 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Details   Intermin results for a small RCT with 40 favipiravir and 20 control patients showing faster viral clearance with favipiravir. There is limited data in this report to evaluate the results. The report indicates that 75% of the control group..
3/18
Late Cai et al., Engineering, doi:10.1016/j.eng.2020.03.007 (Peer Reviewed) pneumonia, ↓68.7%, p=0.04 Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Details   Comparison of 35 FPV patients and 35 LPV/RTV patients, showing significant improvements in chest CT and faster viral clearance with FPV.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Molnupiravir
Nitazoxanide
Povidone-Iodine
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Feedback